175 related articles for article (PubMed ID: 25460346)
1. Anti-dengue virus envelope protein domain III IgG ELISA among infants with primary dengue virus infections.
Libraty DH; Zhang L; Obcena A; Brion JD; Capeding RZ
Acta Trop; 2015 Feb; 142():103-7. PubMed ID: 25460346
[TBL] [Abstract][Full Text] [Related]
2. Recombinant envelope protein-based enzyme immunoassay for IgG antibodies is comparable to neutralization tests for epidemiological studies of dengue infection.
Rocha ES; Oliveira JG; Santos JR; Rodrigues GO; Figueiredo LB; Pessanha JE; Proietti FA; Fonseca FG; Bonjardim CA; Ferreira PC; Kroon EG
J Virol Methods; 2013 Jan; 187(1):114-20. PubMed ID: 23018061
[TBL] [Abstract][Full Text] [Related]
3. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.
Libraty DH; Acosta LP; Tallo V; Segubre-Mercado E; Bautista A; Potts JA; Jarman RG; Yoon IK; Gibbons RV; Brion JD; Capeding RZ
PLoS Med; 2009 Oct; 6(10):e1000171. PubMed ID: 19859541
[TBL] [Abstract][Full Text] [Related]
4. [Establishment and preliminary application of dengue virus envelope domain III IgG antibody capture enzyme-linked immuno-absorbent assay].
Hu DM; Cai JP; Wang DH; DI B; Qiu LW; Wang YD; Chen Y; Ding XX; Che XY
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Apr; 47(4):363-6. PubMed ID: 23928645
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.
Zidane N; Dussart P; Bremand L; Bedouelle H
BMC Infect Dis; 2013 Jul; 13():302. PubMed ID: 23815496
[TBL] [Abstract][Full Text] [Related]
6. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of dengue virus infection in US travelers who have lived in or traveled to dengue-endemic countries.
Sanchez-Vegas C; Hamer DH; Chen LH; Wilson ME; Benoit C; Hunsperger E; Macleod WB; Jentes ES; Ooi WW; Karchmer AW; Kogelman L; Yanni E; Marano N; Barnett ED
J Travel Med; 2013; 20(6):352-60. PubMed ID: 24165381
[TBL] [Abstract][Full Text] [Related]
8. [To evaluate the neutralizing abilities of anti-dengue virus antibodies with nonstructural protein 1 antigen capture enzyme-linked immunosorbent assay].
Wen K; Ding YQ; Qiu LW; Pan YX; Cai JP; Yue CF; DI B; Che XY
Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Aug; 43(8):680-5. PubMed ID: 20021846
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
[TBL] [Abstract][Full Text] [Related]
10. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
[TBL] [Abstract][Full Text] [Related]
11. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
12. Human monoclonal single-chain antibodies specific to dengue virus envelope protein.
Saokaew N; Poungpair O; Panya A; Tarasuk M; Sawasdee N; Limjindaporn T; Chaicumpa W; Yenchitsomanus P
Lett Appl Microbiol; 2014 Mar; 58(3):270-7. PubMed ID: 24266517
[TBL] [Abstract][Full Text] [Related]
13. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
[TBL] [Abstract][Full Text] [Related]
14. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.
Lai CY; Williams KL; Wu YC; Knight S; Balmaseda A; Harris E; Wang WK
PLoS Negl Trop Dis; 2013; 7(9):e2451. PubMed ID: 24069496
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
Gelanew T; Hunsperger E
Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531
[TBL] [Abstract][Full Text] [Related]
16. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.
Puschnik A; Lau L; Cromwell EA; Balmaseda A; Zompi S; Harris E
PLoS Negl Trop Dis; 2013; 7(6):e2274. PubMed ID: 23785536
[TBL] [Abstract][Full Text] [Related]
17. High frequency of pre-existing neutralizing antibody responses in patients with dengue during an outbreak in Central Brazil.
de Teive E Argolo AF; de Rezende Féres VC; Cordeiro MT; da Silveira LA; Guilarde AO; de Azevedo Marques ET; de Souza WV; Martelli CM
BMC Infect Dis; 2016 Oct; 16(1):546. PubMed ID: 27717314
[TBL] [Abstract][Full Text] [Related]
18. Specific detection of dengue and Zika virus antibodies using envelope proteins with mutations in the conserved fusion loop.
Rockstroh A; Moges B; Barzon L; Sinigaglia A; Palù G; Kumbukgolla W; Schmidt-Chanasit J; Sarno M; Brites C; Moreira-Soto A; Drexler JF; Ferreira OC; Ulbert S
Emerg Microbes Infect; 2017 Nov; 6(11):e99. PubMed ID: 29116222
[TBL] [Abstract][Full Text] [Related]
19. Comparison of plaque- and enzyme-linked immunospot-based assays to measure the neutralizing activities of monoclonal antibodies specific to domain III of dengue virus envelope protein.
Liu L; Wen K; Li J; Hu D; Huang Y; Qiu L; Cai J; Che X
Clin Vaccine Immunol; 2012 Jan; 19(1):73-8. PubMed ID: 22116689
[TBL] [Abstract][Full Text] [Related]
20. [Investigation of dengue virus and yellow fever virus seropositivities in blood donors from Central/Northern Anatolia, Turkey].
Ergünay K; Saygan MB; Aydoğan S; Litzba N; Niedrig M; Pınar A; Us D
Mikrobiyol Bul; 2010 Jul; 44(3):415-24. PubMed ID: 21063991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
